S

Spyre Therapeutics
D

SYRE

99.180
USD
-3.50
(-3.41%)
قبل الجلسة·100.000USD+0.820(+0.83%)
حجم التداول
41,283
الربح لكل سهم
-3
العائد الربحي
-
P/E
-47
حجم السوق
8,612,915,473
المقالات
المزيد

العنوان: Spyre Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting 47, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.